Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107337 | 0.81 | AR (0.42) | PKMHTR6DRD3HTR2CHTT | |
| SCHEMBL14552293 | 0.75 | HTR6 (0.65) | HTR6HTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL18648665 | 0.75 | ADCY6 (0.36) | HTR6HTR2CHTR2B | |
| SCHEMBL18648574 | 0.75 | ADCY6 (0.36) | HTR6HTR2CHTR2B | |
| SCHEMBL1293874 | 0.74 | ESR2 (0.45) | PDE3BPDE3APKM | |
| SCHEMBL12107395 | 0.74 | AR (0.44) | HTR6HTR2CGRM5 | |
| SCHEMBL14552356 | 0.74 | CDK4 (0.39) | HTR2C | |
| SCHEMBL12108483 | 0.72 | AR (0.46) | DRD3HTR2CHTTLMNAHTR2B | |
| SCHEMBL14552345 | 0.72 | NOTUM (0.36) | PDE3BPDE3AHTR2CLMNAALDH1A1 | |
| SCHEMBL5361819 | 0.72 | PDE3B (0.47) | PDE3BPDE3APKMHTR6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1751163-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118549-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012496-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | PDE3B 58/4885PDE3A 84/4885PKM 2702/4885 |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | DRD3, DRD2, SLC6A3 | PDE3B 620/4885PDE3A 460/4885PKM 3966/4885 |
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | PDE3B 47/4885PDE3A 67/4885PKM 2264/4885 |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | PDE3B 58/4885PDE3A 84/4885PKM 2702/4885 |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | PDE3B 58/4885PDE3A 84/4885PKM 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.